BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ASP2138 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ASP2138\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07024615-11060@assetmemo.bio
DTSTAMP:20261121T004537Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:ASP2138: Phase 1 readout est. (NCT07024615)
DESCRIPTION:ASP2138\, phase 1.\nStudy: A Study of ASP2138 Given Before Surg
 ery\, Then Chemotherapy After Surgery\, in People With Pancreatic Ductal C
 ancer\nEstimated primary completion: 31 January 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/asp2138#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07024615
URL:https://assetmemo.bio/drug/asp2138#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05365581-11060@assetmemo.bio
DTSTAMP:20261121T004537Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:ASP2138: Phase 1 readout est. (NCT05365581)
DESCRIPTION:ASP2138\, phase 1.\nStudy: A Study of ASP2138 Given by Itself o
 r Given With Other Cancer Treatments in Adults With Stomach Cancer\, Gastr
 oesophageal Junction Cancer\, or Pancreatic Cancer\nEstimated primary comp
 letion: 31 May 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 asp2138#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05365581
URL:https://assetmemo.bio/drug/asp2138#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07673887-11060@assetmemo.bio
DTSTAMP:20261121T004537Z
DTSTART;VALUE=DATE:20310228
DTEND;VALUE=DATE:20310301
SUMMARY:ASP2138: Phase 3 readout est. (NCT07673887)
DESCRIPTION:ASP2138\, phase 3\, Gastric Cancer.\nStudy: A Study of ASP2138 
 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
 \nEstimated primary completion: 28 February 2031. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/asp2138#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07673887
URL:https://assetmemo.bio/drug/asp2138#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
